Logo image
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
Journal article   Open access   Peer reviewed

Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects

Robert B Couch, Patricia Winokur, Rebecca Brady, Robert Belshe, Wilbur H Chen, Thomas R Cate, Bryndis Sigurdardottir, Amy Hoeper, Irene L Graham, Robert Edelman, …
Vaccine, Vol.25(44), pp.7656-7663
2007
DOI: 10.1016/j.vaccine.2007.08.042
PMCID: PMC2243220
PMID: 17913310
url
https://doi.org/10.1016/j.vaccine.2007.08.042View
Published (Version of record) Open Access

Abstract

To improve immune responses to influenza vaccine, a trivalent inactivated vaccine containing 60 μg of the HA of each component (A/H3N2, A/H1N1, B) was compared to a licensed vaccine containing 15 μg of the HA of each. More local and systemic reactions were reported by subjects given the high dosage but only local pain and myalgias were significantly increased. The high dosage vaccine induced a higher frequency of serum antibody increases (≥4-fold) in both hemagglutination-inhibiting (HAI) and neutralization tests for all three vaccine viruses in the total group as well as subjects vaccinated and those not vaccinated the previous year. Mean titers of antibody attained, the magnitude of antibody increases and the frequencies of persons with final HAI antibody titers ≥1:32, ≥1:64, and ≥1:128 were all greater for the high dosage group in both serologic tests, for all groups, and for all vaccine viruses. These increased immune responses should provide increased protection against influenza in the elderly.
Elderly Influenza Vaccines

Details

Metrics

Logo image